GT201400034A - Compuestos y composiciones como inhibidores de la quinasa c-kit - Google Patents

Compuestos y composiciones como inhibidores de la quinasa c-kit

Info

Publication number
GT201400034A
GT201400034A GT201400034A GT201400034A GT201400034A GT 201400034 A GT201400034 A GT 201400034A GT 201400034 A GT201400034 A GT 201400034A GT 201400034 A GT201400034 A GT 201400034A GT 201400034 A GT201400034 A GT 201400034A
Authority
GT
Guatemala
Prior art keywords
compounds
kit
quinase
inhibitors
compositions
Prior art date
Application number
GT201400034A
Other languages
English (en)
Inventor
Molteni Valentina
Petrassi Hank Michael James
Li Xiaolin
Liu Xiaodong
Loren Jon
Nabakka Juliet
Nguyen Bao
Yeh Vince
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT201400034A publication Critical patent/GT201400034A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA INVENCIÓN PROPORCIONA COMPUESTOS Y COMPOSICIONES FARMACÉUTICAS DE LOS MISMOS, QUE SON ÚTILES COMO INHIBIDORES DE PROTEÍNA QUINASA, ASÍ COMO MÉTODOS PARA USAR TALES COMPUESTOS PARA TRATAR, MEJORAR O PREVENIR UNA AFECCIÓN ASOCIADA CON LA ACTIVIDAD ANORMAL O DESREGULADA QUINASA.EN ALGUNAS REALIZACIONES, LA INVENCIÓN PROPORCIONA MÉTODOS PARA USAR TALES COMPUESTOS PARA TRATAR, MEJORAR O PREVENIR ENFERMEDADES O TRASTORNOS QUE IMPLICAN LA ACTIVACIÓN ANORMAL DE PDGFR (PDGFR [ALFA], [PDGFR BETA)] QUINASAS C-KIT O C-KIT.
GT201400034A 2011-09-01 2014-02-27 Compuestos y composiciones como inhibidores de la quinasa c-kit GT201400034A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161530038P 2011-09-01 2011-09-01

Publications (1)

Publication Number Publication Date
GT201400034A true GT201400034A (es) 2015-02-19

Family

ID=46829904

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201400034A GT201400034A (es) 2011-09-01 2014-02-27 Compuestos y composiciones como inhibidores de la quinasa c-kit

Country Status (29)

Country Link
US (3) US8569283B2 (es)
EP (1) EP2751104B1 (es)
JP (1) JP6134319B2 (es)
KR (1) KR101962495B1 (es)
CN (1) CN103797011B (es)
AP (1) AP2014007493A0 (es)
AR (1) AR087753A1 (es)
AU (1) AU2012302042B2 (es)
BR (1) BR112014004560A2 (es)
CA (1) CA2845169C (es)
CL (1) CL2014000492A1 (es)
CO (1) CO6900141A2 (es)
CR (1) CR20140107A (es)
CU (1) CU20140024A7 (es)
EA (1) EA026152B1 (es)
ES (1) ES2761332T3 (es)
GT (1) GT201400034A (es)
IL (1) IL231227A0 (es)
MA (1) MA35460B1 (es)
MX (1) MX339937B (es)
PE (1) PE20140909A1 (es)
PL (1) PL2751104T3 (es)
PT (1) PT2751104T (es)
SG (1) SG2014014369A (es)
TN (1) TN2014000068A1 (es)
TW (1) TW201313717A (es)
UY (1) UY34301A (es)
WO (1) WO2013033167A1 (es)
ZA (1) ZA201401175B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9199981B2 (en) * 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
ES2761332T3 (es) 2011-09-01 2020-05-19 Novartis Ag Compuestos y composiciones como inhibidores de la cinasa c-kit
DK3007689T3 (en) 2013-01-10 2018-06-14 Pulmokine Inc NON-SELECTIVE KINASE INHIBITORS
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
ES2959419T3 (es) 2013-10-11 2024-02-26 Pulmokine Inc Formulaciones secas por aspersión
US20150288928A1 (en) * 2014-04-08 2015-10-08 Sony Corporation Security camera system use of object location tracking data
CN105384738B (zh) * 2014-08-21 2017-08-29 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
BR112017028318B1 (pt) 2015-07-02 2024-02-20 Janssen Sciences Ireland Uc Composto antibacteriano, seu uso, processo para sua preparação,produto que o contém, composição farmacêutica e combinação
US10474987B2 (en) * 2015-08-05 2019-11-12 Whirlpool Corporation Object recognition system for an appliance and method for managing household inventory of consumables
WO2017214413A1 (en) * 2016-06-08 2017-12-14 Chrysalis, Inc. Imidazo[1,2-a]pyridine derivatives as histone demethylase inhibitors
BR112018075939A2 (pt) 2016-06-16 2019-04-09 Janssen Sciences Ireland Unlimited Company compostos heterocíclicos como antibacterianos
CA3026010A1 (en) 2016-06-16 2017-12-21 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacterials
WO2018081567A1 (en) 2016-10-27 2018-05-03 Pulmokine, Inc. Combination therapy for treating pulmonary hypertension
US20180162291A1 (en) * 2016-12-12 2018-06-14 Wipro Limited System and method of dynamically adjusting field of view of an image capturing device
BR112019017901A2 (pt) 2017-03-01 2020-05-12 Janssen Sciences Ireland Unlimited Company Terapia de combinação
BR112020008834A2 (pt) 2017-11-02 2020-12-22 Calico Life Sciences Llc Moduladores da via de estresse integrada
KR102625224B1 (ko) * 2018-10-31 2024-01-15 주식회사 큐로젠 피라졸-온 유도체를 유효성분으로 포함하는 자가면역질환의 예방, 개선 또는 치료용 조성물
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
MX2021013814A (es) * 2019-05-13 2022-02-10 Novartis Ag Formas cristalinas de n-(5-(5-((1r,2s)-2-fluorociclopropil)-1,2,4- oxadiazol-3-yl)-2- metilfenil)imidazo[1,2-a]piridin-3-carboxamida.
JP2022548247A (ja) 2019-09-13 2022-11-17 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー 抗菌化合物
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US11767319B2 (en) 2020-07-15 2023-09-26 Third Harmonic Bio, Inc. Crystalline forms of a selective c-kit kinase inhibitor
TW202237097A (zh) 2020-11-19 2022-10-01 美商第三諧波生物公司 選擇性ｃ－ｋｉｔ激酶抑制劑之醫藥組合物及其製造及使用方法
KR20230157400A (ko) 2021-03-16 2023-11-16 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 항박테리아성 화합물
WO2022194905A1 (en) 2021-03-17 2022-09-22 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
EP4308579A1 (en) 2021-03-17 2024-01-24 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
AR127483A1 (es) 2021-10-28 2024-01-31 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos
WO2024089170A1 (en) 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
AU2003251561A1 (en) 2002-06-20 2004-01-06 Beacon Looms, Inc. Knitted electrical conductor fabric
SI1786799T1 (sl) 2004-09-09 2012-12-31 Natco Pharma Limited Novi derivati fenilaminopirimidina kot inhibitorji BCR-ABL kinaze
EP2942349A1 (en) 2004-12-23 2015-11-11 Deciphera Pharmaceuticals, LLC Enzyme modulators and treatments
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
CA2668190A1 (en) 2006-11-03 2008-05-15 Irm Llc Compounds and compositions as protein kinase inhibitors
MX2013005454A (es) * 2010-11-15 2013-06-24 Abbvie Inc Inhibidores de nampt y rock.
US20130023751A1 (en) 2011-07-18 2013-01-24 Samuel Victor Lichtenstein Water retention monitoring
JP2014525450A (ja) 2011-09-01 2014-09-29 アイアールエム・リミテッド・ライアビリティ・カンパニー ｃ−Ｋｉｔキナーゼ阻害剤としての化合物および組成物
WO2013033620A1 (en) 2011-09-01 2013-03-07 Irm Llc Compounds and compositions as pdgfr kinase inhibitors
ES2761332T3 (es) 2011-09-01 2020-05-19 Novartis Ag Compuestos y composiciones como inhibidores de la cinasa c-kit
US9199981B2 (en) 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors

Also Published As

Publication number Publication date
EA026152B1 (ru) 2017-03-31
CR20140107A (es) 2014-05-02
PL2751104T3 (pl) 2020-04-30
AR087753A1 (es) 2014-04-16
AP2014007493A0 (en) 2014-03-31
MX339937B (es) 2016-06-17
CA2845169A1 (en) 2013-03-07
KR20140075692A (ko) 2014-06-19
CL2014000492A1 (es) 2014-10-03
US20140031333A1 (en) 2014-01-30
AU2012302042B2 (en) 2016-03-31
MA35460B1 (fr) 2014-09-01
US20140228347A1 (en) 2014-08-14
EA201490545A1 (ru) 2014-07-30
US9023839B2 (en) 2015-05-05
BR112014004560A2 (pt) 2017-04-04
CA2845169C (en) 2022-04-19
TN2014000068A1 (en) 2015-07-01
TW201313717A (zh) 2013-04-01
KR101962495B1 (ko) 2019-03-26
PE20140909A1 (es) 2014-07-20
MX2014002484A (es) 2014-11-25
US8754071B2 (en) 2014-06-17
IL231227A0 (en) 2014-04-30
EP2751104B1 (en) 2019-09-25
JP6134319B2 (ja) 2017-05-24
UY34301A (es) 2013-04-05
WO2013033167A1 (en) 2013-03-07
JP2014525448A (ja) 2014-09-29
US8569283B2 (en) 2013-10-29
CO6900141A2 (es) 2014-03-20
CN103797011A (zh) 2014-05-14
PT2751104T (pt) 2019-12-16
EP2751104A1 (en) 2014-07-09
AU2012302042A1 (en) 2014-04-17
CU20140024A7 (es) 2014-04-24
ZA201401175B (en) 2015-01-28
CN103797011B (zh) 2016-03-30
ES2761332T3 (es) 2020-05-19
SG2014014369A (en) 2014-09-26
US20130059832A1 (en) 2013-03-07

Similar Documents

Publication Publication Date Title
GT201400034A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
ECSP23004573A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
GT201300209A (es) Compuestos y composiciones como inhibidores de la trk
GT201400036A (es) Compuestos y composiciones como inhibidores de la quinasa c - kit
CO2017011851A2 (es) Compuestos novedosos
CU20140139A7 (es) Compuestos y composiciones para modular la actividad de egfr
UY33597A (es) Compuestos y composiciones como inhibidores de la trk
GT201400063A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
NI201600071A (es) Compuestos de inhibidor de autotaxina
ECSP13012869A (es) Compuestos y métodos para la modulación de quinasas e indicaciones para los mismos
DOP2014000233A (es) Compuestos de microarn y métodos de modulación de la actividad de mir-21
ECSP14013159A (es) Compuestos inhibidores de metaloenzimas
MX2016003486A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
DOP2012000257A (es) Derivados del acido 1-amino-2-ciclopropiletilboronico
EA201490542A1 (ru) Соединения и композиции в качестве pdgfr киназных ингибиторов
BR112014004319A2 (pt) compostos e composições como inibidores de c-kit cinase
DOP2014000253A (es) Inhibidores del nampt
EA201692143A1 (ru) Производные аминопиразина в качестве ингибиторов фосфатидилинозитол-3-киназы
BR112015000051A2 (pt) tratamento de distúrbios inflamatórios da pele
GT201500124A (es) Forma sòlida de un derivado de dihidro-pirido-oxazina
CR20140289A (es) Derivados de quinolina como inhibidores de la enzima pde10a
CU20140102A7 (es) Compuestos de oxazolidin-2- ona y usos de los mismos como inhibidores de la p13ks
ECSP13012484A (es) Nuevos moduladores de trpv3
DOP2009000084A (es) Triazoles biciclicos como moduladores de la proteina cinasa